news
EC approves Avastin plus Tarceva in NSCLC
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
List view / Grid view
Roche
news
EC approves MabThera for chronic lymphocytic leukaemia
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
news
Positive results from Phase III study of Gazyva in follicular lymphoma
27 May 2016 | By Victoria White, Digital Content Producer
Roche has announced positive results from the pivotal Phase III GALLIUM study.
news
Lariam only to be considered as a last resort, says Defence Committee
24 May 2016 | By Victoria White, Digital Content Producer
Lariam, the anti-malarial drug sometimes prescribed to British troops, should be considered only as a drug of last resort, says the Defence Committee...
news
Study reveals Alecensa is effective against specific type of lung cancer in Japanese patients
20 May 2016 | By Katie Sadler
Roche has announced that Alecensa, an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death in Japanese people with advanced or recurrent, ALK-positive non-small cell lung cancer (NSCLC).
news
FDA grants priority review for Roche’s atezolizumab in NSCLC
11 April 2016 | By Victoria White, Digital Content Producer
The FDA has granted a priority review for atezolizumab for the treatment of locally advanced or metastatic NSCLC that expresses the protein PD-L1...
news
FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
news
Roche provides update on two Phase III studies of lebrikizumab in asthma
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
news
Breakthrough Therapy Designation for ocrelizumab in PPMS
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
news
Alecensa trial stopped early; meets primary endpoint
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
news
FDA grants third venetoclax Breakthrough Therapy Designation
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
FDA grants breakthrough therapy designation to venetoclax combo in CLL
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
news
One-hour diagnosis of heart attack possible with Roche’s troponin T test
13 January 2016 | By Victoria White
Results from a study demonstrate that Roche’s cardiac troponin T-high-sensitivity test shortens the time to diagnose heart attack to one hour from three hours or more...
news
FDA grants Priority Review for venetoclax NDA
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
